Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 19 | 2026 | 22 | 4.390 |
Why?
|
| Graft vs Host Disease | 13 | 2025 | 17 | 2.690 |
Why?
|
| Transplantation Conditioning | 10 | 2026 | 11 | 1.900 |
Why?
|
| Mutation | 10 | 2025 | 97 | 1.550 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2025 | 8 | 1.550 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2020 | 24 | 1.470 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2025 | 7 | 1.390 |
Why?
|
| Humans | 42 | 2026 | 6794 | 1.330 |
Why?
|
| Primary Myelofibrosis | 2 | 2025 | 3 | 1.170 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 45 | 1.060 |
Why?
|
| Retrospective Studies | 20 | 2026 | 681 | 1.060 |
Why?
|
| Neoplasms | 2 | 2021 | 92 | 1.000 |
Why?
|
| Adult | 22 | 2025 | 2113 | 0.990 |
Why?
|
| Aged | 22 | 2026 | 1539 | 0.960 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2025 | 1 | 0.950 |
Why?
|
| Lung Diseases | 1 | 2025 | 9 | 0.940 |
Why?
|
| Thrombosis | 1 | 2025 | 13 | 0.940 |
Why?
|
| Liver Diseases | 1 | 2025 | 19 | 0.940 |
Why?
|
| Middle Aged | 23 | 2026 | 2108 | 0.920 |
Why?
|
| Melphalan | 4 | 2025 | 4 | 0.920 |
Why?
|
| Vidarabine | 4 | 2025 | 4 | 0.910 |
Why?
|
| Male | 22 | 2026 | 3671 | 0.840 |
Why?
|
| Female | 23 | 2026 | 4060 | 0.820 |
Why?
|
| Hematology | 1 | 2023 | 1 | 0.790 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 2 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 21 | 0.780 |
Why?
|
| Cyclophosphamide | 5 | 2025 | 8 | 0.760 |
Why?
|
| Transplantation, Homologous | 7 | 2026 | 16 | 0.720 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 1 | 0.690 |
Why?
|
| T-Lymphocytes | 3 | 2025 | 20 | 0.650 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 1 | 0.560 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1 | 0.560 |
Why?
|
| Medical Oncology | 2 | 2018 | 10 | 0.560 |
Why?
|
| Organophosphorus Compounds | 1 | 2018 | 5 | 0.560 |
Why?
|
| Pyrimidines | 1 | 2018 | 17 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 17 | 0.550 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 13 | 0.540 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 72 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 1 | 2022 | 420 | 0.510 |
Why?
|
| Tacrolimus | 3 | 2025 | 6 | 0.490 |
Why?
|
| Young Adult | 10 | 2025 | 567 | 0.470 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 2 | 2025 | 3 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 23 | 0.440 |
Why?
|
| Antibodies, Bispecific | 2 | 2025 | 3 | 0.430 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 497 | 0.380 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 51 | 0.370 |
Why?
|
| Disease-Free Survival | 5 | 2026 | 24 | 0.330 |
Why?
|
| Unrelated Donors | 3 | 2025 | 3 | 0.330 |
Why?
|
| Animals | 5 | 2025 | 1875 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 88 | 0.280 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2024 | 2 | 0.270 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2024 | 2 | 0.270 |
Why?
|
| Recurrence | 2 | 2025 | 55 | 0.270 |
Why?
|
| Prognosis | 6 | 2026 | 220 | 0.270 |
Why?
|
| Mice | 3 | 2025 | 746 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 29 | 0.260 |
Why?
|
| Remission Induction | 2 | 2024 | 5 | 0.260 |
Why?
|
| Adolescent | 6 | 2025 | 869 | 0.260 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2025 | 4 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 31 | 0.250 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 5 | 0.240 |
Why?
|
| Treatment Outcome | 4 | 2025 | 500 | 0.230 |
Why?
|
| Disease Management | 1 | 2025 | 33 | 0.230 |
Why?
|
| rho-Associated Kinases | 1 | 2025 | 2 | 0.230 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 2 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 17 | 0.230 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2025 | 1 | 0.230 |
Why?
|
| Cystitis | 1 | 2025 | 4 | 0.230 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2025 | 6 | 0.230 |
Why?
|
| Renal Insufficiency | 1 | 2025 | 21 | 0.230 |
Why?
|
| Myeloablative Agonists | 1 | 2024 | 2 | 0.220 |
Why?
|
| Survival Rate | 5 | 2025 | 111 | 0.220 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2024 | 1 | 0.220 |
Why?
|
| Spliceosomes | 1 | 2024 | 1 | 0.220 |
Why?
|
| MicroRNAs | 1 | 2025 | 54 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 19 | 0.220 |
Why?
|
| Whole-Body Irradiation | 1 | 2024 | 4 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 24 | 0.210 |
Why?
|
| Staurosporine | 1 | 2024 | 4 | 0.210 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 7 | 0.210 |
Why?
|
| Cyclosporine | 1 | 2023 | 7 | 0.210 |
Why?
|
| Methotrexate | 1 | 2023 | 11 | 0.210 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 14 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 1 | 0.200 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2023 | 1 | 0.200 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 1 | 0.200 |
Why?
|
| B7-H1 Antigen | 2 | 2019 | 3 | 0.190 |
Why?
|
| Precision Medicine | 2 | 2020 | 13 | 0.190 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2022 | 1 | 0.190 |
Why?
|
| Disease Progression | 1 | 2023 | 170 | 0.190 |
Why?
|
| Safety-net Providers | 1 | 2020 | 24 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 50 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 3 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 23 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 57 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 63 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 1 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 16 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 1 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2018 | 11 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 24 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 17 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 18 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 170 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2022 | 457 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 100 | 0.120 |
Why?
|
| Mice, Inbred NOD | 2 | 2025 | 3 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 156 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2025 | 17 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 1 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2014 | 23 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2025 | 258 | 0.100 |
Why?
|
| Child | 2 | 2025 | 524 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 26 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 23 | 0.080 |
Why?
|
| Risk Factors | 2 | 2024 | 767 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 268 | 0.070 |
Why?
|
| Morbidity | 1 | 2026 | 21 | 0.060 |
Why?
|
| Delirium | 1 | 2026 | 4 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2026 | 19 | 0.060 |
Why?
|
| Cytarabine | 1 | 2025 | 1 | 0.060 |
Why?
|
| Idarubicin | 1 | 2025 | 1 | 0.060 |
Why?
|
| Cladribine | 1 | 2025 | 1 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2025 | 2 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2025 | 16 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 38 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 2 | 0.060 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2024 | 1 | 0.060 |
Why?
|
| RNA Splicing Factors | 1 | 2024 | 1 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 1 | 0.060 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 1 | 0.060 |
Why?
|
| Janus Kinase 2 | 1 | 2024 | 5 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2024 | 2 | 0.050 |
Why?
|
| Genomics | 1 | 2024 | 13 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 17 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2024 | 28 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2024 | 13 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 38 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2025 | 167 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2024 | 1 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2024 | 26 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2024 | 197 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2023 | 4 | 0.050 |
Why?
|
| Sirolimus | 1 | 2023 | 6 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 14 | 0.050 |
Why?
|
| Adoptive Transfer | 1 | 2022 | 3 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2023 | 331 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 2 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 7 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2020 | 13 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 42 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epithelium | 1 | 2019 | 22 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 15 | 0.040 |
Why?
|
| Breast | 1 | 2019 | 9 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 6 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 63 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 2 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 6 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 8 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 169 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 22 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2017 | 1 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2017 | 2 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 5 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 13 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 45 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 63 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 54 | 0.030 |
Why?
|